When was Zymedi founded?

Zymedi was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Zymedi located?

Zymedi is headquartered in Incheon, South Korea.

Who is the current CEO of Zymedi?

Sunghoon Kim and Nam Hoon Kwon s of Zymedi.

How many employees does Zymedi have?

As of Jun 30, 2026, the latest employee count at Zymedi is 11.

Is Zymedi a funded company?

Zymedi is a funded company, having raised a total of $29.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2021.

When was the latest funding round of Zymedi?

Zymedi's latest funding was a $***** Series A round on May 30, 2023, with participation from 7 investors. Its primary sector is Metabolic Diseases. In South Korea, the Metabolic Diseases sector has seen $21.5M in funding in 2026 to date.

Where does Zymedi rank among its competitors?

Zymedi ranks 56th amongst 148 active competitors, of which 52 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Drug Farm, which secured $55M in Jul, 2026.

Who are the top competitors of Zymedi?

Zymedi's top competitors include Nimbus Therapeutics, Madrigal Pharmaceuticals and Mammoth. Among them, Drug Farm secured the most recent funding round in July, 2026.

Zymedi - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for multiple diseases. It offers Aminoacyl-tRNA Synthetase-based drugs which include ZM-A001 for Pulmonary arterial hypertension, ZM-C001 for NASH (Non-alcoholic steatohepatitis), and ZM-C101 for colorectal cancer.

Website: zymedi.com
Email ID: *****@zymedi.com
Phone Number: +82 **********

Key Metrics

Founded Year

2019

Location

Incheon, South Korea

Stage

Series A

Total Funding

$29.5M in 2 rounds

Latest Funding Round

Series A, May 30, 2023, $*****

Investors

Industrial Bank of Korea & 7 more

Ranked

56^th among 148 active competitors

Employee Count

11 as on Jun 30, 2026

Similar Companies

Nimbus Therapeutics & 108 more

View Zymedi's full profile

Zymedi has raised a total funding of $29.5M over 2 rounds. Its first funding round was on 2021. Its latest funding round was a Series A round on May 30, 2023 for $*****. 7 investors participated in its latest round. Zymedi has 8 institutional investors.

Here is the list of recent funding rounds of Zymedi:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 30, 2023	3721092	Series A	1572299	4377126	6546478	9944505
2021	1020	Series A	5486	9356	4337	4692

Access funding benchmarks and valuations. Sign up today!

View details of Zymedi's funding rounds and investors

The founders of Zymedi is Sunghoon Kim. Nam Hoon Kwon is the CEO of Zymedi.

Here are the details of Zymedi's key team members:

Sunghoon Kim: Founder & CEO of Zymedi.
Nam Hoon Kwon: CEO of Zymedi.

View details of Zymedi's Founder profiles and Board Members

Zymedi's employee count trend

Zymedi has 11 employees as of Jun 26. Here is Zymedi's employee count trend over the years:

Uncover Zymedi's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zymedi include Nimbus Therapeutics, Madrigal Pharmaceuticals and Mammoth. Here is the list of Top 10 competitors of Zymedi, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Madrigal Pharmaceuticals 2011, Conshohocken (United States), Acquired	Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis	$38.4M	Avoro Capital, Bay City Capital & 3 others	66/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
4th	Drug Farm 2015, Shanghai (China), Series D	Developer of a novel treatment for metabolic diseases	$138M	Shanghai Pudong Leading Area Investment Center, Zhejiang Private Enterprise United Investment ... & 12 others	64/100
5th	Intercept Pharmaceuticals 2002, New York City (United States), Acquired	Developer of therapeutics to treat progressive non-viral liver diseases	$121M	Orbimed, JAFCO Group & 7 others	63/100
6th	Mirum Pharmaceuticals 2018, Menlo Park (United States), Public	Developer of small molecule based therapeutics to treat rare diseases	$120M	New Enterprise Associates, Oberland Capital ... & 9 others	61/100
7th	Mineralys Therapeutics 2020, Radnor (United States), Public	Developer of therapy for the treatment of hypertension	$158M	Andera Partners, Samsara BioCapital & 15 others	61/100
8th	Akero Therapeutics 2017, San Francisco (United States), Acquired	Developer of small molecule therapeutics for metabolic disorders	$135M	Atlas Venture, Janus Henderson Investors ... & 12 others	61/100
9th	Altimmune 1997, Gaithersburg (United States), Acquired	Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors	$58M	Gershon Capital, Fidelis Capital & 15 others	61/100
10th	Terns Pharmaceutical 2017, San Mateo (United States), Acquired	Developer of therapies for treating liver disease and cancer	$208M	Lilly Asia Ventures, Orbimed & 6 others	60/100
56th	Zymedi 2019, Incheon (South Korea), Series A	Developer of therapeutics for multiple diseases	$29.5M	Company K Partners, Industrial Bank of Korea ... & 6 others	40/100